* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *
Full Coverage

Myriad Genetics to partner with H. Lundbeck on Flurizan

marketwatch.com
May 22, 2008
        
Story Timeline:  144 days

LONDON (MarketWatch) -- Myriad Genetics said it will get $100 million upfront and up to $250 million from regulatory approvals from H. Lundbeck A/S in return for European commercialization rights to Alzheimer's disease drug candiate Flurizan. Myriad also will get escalating royalties of 20% to... [read full story]                    

Add Comment
Latest article on this story:

Myriad Making Good Deals (at Motley Fool)

 yahoo.com May 23, 2008
First article on this story:

Myriad Genetics Selects Lundbeck as European Partner for Flurizan

 tmcnet.com May 22, 2008
Selected publications with coverage of this story:
ibtimes.com redorbit.com marketwire.com marketwatch.com yahoo.com earthtimes.org euroinvestor.co.uk ad-hoc-news.de pharmiweb.co.uk tmcnet.com finanznachrichten.de
RELATED
Found 22 documents:
                   

Myriad Making Good Deals (at Motley Fool)

yahoo.com
May 23, 2008
        

By Brian Lawler May 23, 2008 Comments (0) Some drug deals are better than others. Yesterday, Rule Breakers pick Myriad Genetics (Nasdaq: MYGN) announced a particularly strong partnership deal for its lead drug, Flurizan. Flurizan is currently in late-stage testing as a treatment for Alzheimer's...

Myriad's Flurizan Deal Is a Hedged Bet (at TheStreet.com)

yahoo.com
May 22, 2008
        

Myriad Genetics MYGN surprised investors early Thursday selling outside-the-U.S. rights to its Alzheimer's drug Flurizan -- mere weeks before late-stage data will offer more clues to the drug's approvability. Danish company Lundbeck will pay Myriad $100 million upfront...

                   

Myriad Gets $100M Upfront in European Deal for Flurizan

tmcnet.com
May 22, 2008
        

250M Potential As its Flurizan product nears what could be a multi-billion dollar market in Alzheimer's disease, Myriad Genetics Inc. launched its global strategy by signing a commercialization deal in Europe with J. Lundbeck AS for $100 million upfront with a potential for $250 million. Myriad...

Biotech Stocks: Drug stocks gain; Myriad climbs on drug-licensing deal

marketwatch.com
May 22, 2008
        

Drug stocks gain; Myriad climbs on Flurizan deal BOSTON (MarketWatch) -- Drug stocks gained Thursday as Myriad Genetics Inc. shares climbed on news that the company has signed a deal with Swedish drug conglomerate H. Lundbeck A/S for the European commercialization of its Alzheimer's drug...

Biotech Stocks: Drug stocks gain; Myriad climbs on drug-licensing deal (at MarketWatch)

yahoo.com
May 22, 2008
        

Drug stocks gain; Myriad climbs on Flurizan deal BOSTON (MarketWatch) -- Drug stocks gained Thursday as Myriad Genetics Inc. shares climbed on news that the company has signed a deal with Swedish drug conglomerate H. Lundbeck A/S for the European commercialization of its Alzheimer's drug...

                   

Lundbeck: Myriad Deal is a High Risk High Reward Strategy

redorbit.com
May 22, 2008
        

Posted on: Thursday, 22 May 2008, 11:53 CDT Lundbeck has acquired the European commercialization rights to Myriad's new Alzheimer's treatment, Flurizan. However, late stage failures are common in the Alzheimer's disease drug pipeline and, as such, Lundbeck is taking on a high risk investment;...

yahoo.com: Reuters Deals Today yahoo.com

Myriad licenses Alzheimer's drug to Lundbeck (at Reuters)

yahoo.com
May 22, 2008
        

LOS ANGELES, May 22 (Reuters) - Myriad Genetics Inc (MYGN.O: ) said on Thursday that Denmark's H Lundbeck A/S (LUN.CO: ) will acquire European rights to its experimental Alzheimer's disease drug Flurizan, but the deal will increase Myriad's quarterly loss. Lundbeck will pay Myriad an initial $100...

UPDATE - Lundbeck buys European rights to Alzheimer's drug (at Reuters)

yahoo.com
May 22, 2008
        

By Gelu Sulugiuc COPENHAGEN, May 22 (Reuters) - Danish pharmaceutical group Lundbeck (LUN.CO: ) said on Thursday it had acquired the European rights to Myriad Genetics' Flurizan, an experimental Alzheimer's drug it hopes can become the company's next blockbuster. Lundbeck will pay Myriad (MYGN.O:...

Myriad Genetics Sells Flurizan Licensing Rights (at TheStreet.com)

yahoo.com
May 22, 2008
        

Myriad Genetics MYGN said early Thursday that it sold rights outside the U.S. rights to its late-stage Alzheimer's drug Flurizan. The biotech company struck a deal worth as much as $350 million with Lundbeck A/S. The Danish company will pay Myriad $100 million upfront and up to $250 million in...

Biotech Stocks: Drug stocks mixed; Myriad gains on Alzheimer's deal (at MarketWatch)

yahoo.com
May 22, 2008
        

Drug stocks mixed; Myriad climbs on Alzheimer's deal BOSTON (MarketWatch) -- Drug stocks were mixed in early action Thursday with shares of Myriad Genetics Inc. climbing on news that it has signed a deal with Swedish drug conglomerate H. Lundbeck A/S for the European commercialization of Myriad's...

1 2 3 next

               

Related categories

H. Lundbeck A/S, Myriad Genetics